Cargando…
Palliative treatment of malignant ascites: profile of catumaxomab
Malignant ascites is the abnormal accumulation of fluid in the peritoneal cavity associated with several intrapelvic and intra-abdominal malignancies. The development of ascites leads to significant symptoms and poor quality of life for the cancer patient. Available therapies for palliation include...
Autores principales: | Ammouri, Lila, Prommer, Eric E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2880345/ https://www.ncbi.nlm.nih.gov/pubmed/20531969 |
Ejemplares similares
-
Review of catumaxomab in the treatment of malignant ascites
por: Sebastian, Martin
Publicado: (2010) -
Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
por: Ott, Marion G, et al.
Publicado: (2012) -
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
por: Heiss, Markus M, et al.
Publicado: (2010) -
Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab
por: Seeber, Andreas, et al.
Publicado: (2015) -
Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro
por: Seeber, Andreas, et al.
Publicado: (2015)